Literature DB >> 3880181

Studies on endothelial cell cytotoxic activity in sera of patients with progressive systemic sclerosis, Raynaud syndrome, rheumatoid arthritis, and systemic lupus erythematosus.

F Drenk1, H Mensing, A Serbin, H Deicher.   

Abstract

Using human umbilical cord endothelial cell cultures and a modified 3HTdR uptake technique, endothelial cell cytotoxic activity (ECA) has been demonstrated in sera of 95/130 patients with progressive systemic sclerosis (PSS), 14/20 patients with Raynaud syndrome (RS), 52/153 rheumatoid arthritis (RA), and 47/113 systemic lupus erythematosus (SLE) sera. ECA could be enriched by gel filtration from PSS sera in a molecular weight range of 5 k daltons. ECA was partially associated with serum proteins, mainly in the albumin containing fraction, albeit at a lower level of activity. In PSS, no relationship of ECA to the type of skin involvement was observed. ECA appears to be a low molecular weight mediator of, as yet, unknown origin.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3880181     DOI: 10.1007/bf00541353

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  24 in total

1.  Renal proliferative arteriopathies and associated glomerular changes: a light and electron microscopic study.

Authors:  R A Sinclair; T T Antonovych; F K Mostofi
Journal:  Hum Pathol       Date:  1976-09       Impact factor: 3.466

2.  Ultrastructure of cutaneous cellular infiltrates in scleroderma.

Authors:  R Fleischmajer; J S Perlish; W P West
Journal:  Arch Dermatol       Date:  1977-12

3.  Human beta-thromboglobulin inhibits PGI2 production and binds to a specific site in bovine aortic endothelial cells.

Authors:  W Hope; T J Martin; C N Chesterman; F J Morgan
Journal:  Nature       Date:  1979-11-08       Impact factor: 49.962

4.  Histamine, norepinephrine, and bradykinin stimulation of fibroblast growth and modification of serotonin response.

Authors:  R J Boucek; N L Noble
Journal:  Proc Soc Exp Biol Med       Date:  1973-12

Review 5.  Scleroderma. A model for fibrosis.

Authors:  R Fleischmajer; J S Perlish; M Duncan
Journal:  Arch Dermatol       Date:  1983-12

6.  Platelet-derived growth factor. I. High yield purification and evidence for multiple forms.

Authors:  E W Raines; R Ross
Journal:  J Biol Chem       Date:  1982-05-10       Impact factor: 5.157

7.  [Progressive systemic scleroderma. Clinical spectrum and prognostic parameters in 131 patients].

Authors:  C Luderschmidt; I Kaulertz; G König; B Leisner
Journal:  Dtsch Med Wochenschr       Date:  1984-09-14       Impact factor: 0.628

8.  Elevated levels of circulating platelet aggregates and beta-thromboglobulin in scleroderma.

Authors:  M B Kahaleh; I Osborn; E C Leroy
Journal:  Ann Intern Med       Date:  1982-05       Impact factor: 25.391

9.  Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon.

Authors:  M B Kahaleh; I Osborn; E C LeRoy
Journal:  Ann Intern Med       Date:  1981-04       Impact factor: 25.391

Review 10.  Systemic sclerosis--a microvascular disorder?

Authors:  M I Jayson
Journal:  J R Soc Med       Date:  1983-08       Impact factor: 18.000

View more
  7 in total

1.  IgG and IgM anti-endothelial cell antibodies in patients with collagen-vascular disorders.

Authors:  N P Quadros; P J Roberts-Thomson; A S Gallus
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

2.  Endothelial cytotoxic activity (ECA) in sera of patients with livedo racemosa generalisata Ehrmann.

Authors:  F Drenk; D Lubach; C Schwabe; H Deicher
Journal:  Arch Dermatol Res       Date:  1987       Impact factor: 3.017

3.  Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension.

Authors:  S A Kharitonov; J B Cailes; C M Black; R M du Bois; P J Barnes
Journal:  Thorax       Date:  1997-12       Impact factor: 9.139

4.  Mouse monoclonal antibodies specific for endothelial cells.

Authors:  F Drenk; U Sander; U Alheid; A Serbin; H Deicher
Journal:  Mol Cell Biochem       Date:  1987-07       Impact factor: 3.396

5.  Cytotoxic effects of sera from patients with systemic scleroderma: comparison of three different in vitro methods.

Authors:  S Majewski; M Błaszczyk; S Jabłonska; L Rudnicka; M Waşik; A Skiendzielewska; B Makieła
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

6.  Measurement and characterisation of circulating anti-endothelial cell IgG in connective tissue diseases.

Authors:  J Rosenbaum; B E Pottinger; P Woo; C M Black; S Loizou; M A Byron; J D Pearson
Journal:  Clin Exp Immunol       Date:  1988-06       Impact factor: 4.330

Review 7.  Vascular disease in scleroderma.

Authors:  Fredrick M Wigley
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.